Photo taken from Rami Manochakian/Twitter
Oct 4, 2023, 17:57
Rami Manochakian: Takeda Oncology announced voluntary WITHDRAWAL of Mobocertinib (in the US and globally) for patients with advanced EGFR, Exon20 insertion mutation-positive non-small cell lung cancer, after negative exclaim2 trial.
Rami Manochakian, Associate Professor and Hematology/Oncology Fellowship Director at Mayo Clinic, shared on X/Twitter:
“Hot off the press.
Takeda Oncology announced voluntary WITHDRAWAL of Mobocertinib (in the US and globally) for patients with advanced EGFR, Exon20 insertion mutation-positive non-small cell lung cancer, after negative Exclaim2 trial.”
For deteils click here.
Source: Rami Manochakian/Twitter
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 2, 2024, 14:46
Nov 2, 2024, 12:52
Nov 2, 2024, 12:12
Nov 2, 2024, 12:09
Nov 2, 2024, 11:23